Application of lysozyme and dequalinium chloride in the treatment of acute respiratory diseases of the upper respiratory tract in children
Keywords:children, acute respiratory infections, interferon gamma, lysozyme, dequalinium chloride
Background. Acute viral respiratory infections — a group of the most common diseases that manifest primarily by the catarrhal syndrome with oropharyngeal involvement and require topical application of antiseptics. The purpose was to study the clinical features of pharyngeal and laryngeal lesions in acute respiratory infections in different regions of Ukraine, to evaluate the effectiveness and safety of Lizak on a large clinical material and its ability to influence the activity of native immunity. Materials and methods. 25,229 children aged 4 to 18 years with acute respiratory infections were examined, which manifested by the inflammatory process in the oropharynx. General clinical, immunological, bacteriological studies were carried out. Results. It was established that the use of Lizak in clinical practice is effective and leads to a decrease in the severity of clinical signs of inflammation in the oropharynx, controls dry mouth, pain syndrome, restores the voice function. When studying the correlation between clinical and anamnestic data, it was found that the most significant relationship was observed between tonsillitis and the severity of the temperature response on the first and third days after treatment initiation (r = 0.43 and 0.69, respectively), the presence of tonsillitis also correlated with the intensity of throat pain (r = 0.46) and the presence of cough on day 7 of the disease (r = 0.39). At the same time, the severity of cough on the first and third days of the disease correlated with acute laryngitis (r = 0.51 and 0.36, respectively). Hoarseness correlated with the degree of dryness in the oropharynx (r = 0.47) and was characteristic of laryngitis. To determine the immunological effectiveness of Lizak, 124 children aged 7–12 years with acute respiratory infections and oropharyngeal lesions were examined. It was found that interferon gamma level in the oropharyngeal fluid and blood serum tended to decrease indicating a decrease in the activity of inflammatory process in the oropharynx. It is concluded that Lizak reducing the intensity of the inflammatory process in the oropharynx can influence the level of proinflammatory cytokines, in particular interferon gamma. During the bacteriological examination of the oropharyngeal microflora in patients under observation, an increase in the number of pathogenic and opportunistic microorganisms was observed before the treatment. After the application of Lizak, the microbiocenosis was restored mainly due to a decrease in the number of pathogenic and opportunistic flora (S.aureus, Candida albicans, etc.) and an increase in the number of indigenous flora. Lizak did not have side effects in most cases, although a small number of patients (0.76 %) had signs of allergic reaction (sore throat, uvular edema, unusual taste). The efficacy of Lizak was evaluated by doctors and patients in 99 % of cases as good. Conclusions. Application of Lizak in clinical practice is effective and leads to a decrease in the severity of clinical signs of inflammation in the oropharynx, controls dry mouth, pain syndrome, restores the voice function, reduces the severity of inflammatory process in the oropharynx and affects the level of proinflammatory cytokines, in particular interferon gamma, restores microbiocenosis of the oropharynx by reducing the number of pathogenic and opportunistic flora (S.aureus, Candida albicans, etc.) and increasing the number of indigenous flora. Lizak has good tolerability and is effective in 99 % of cases.
Tkachenko VN. Differential diagnosis of exacerbations of chronic pharyngitis. Journal of ear, nose and throat diseases. 2011;(3):27-28. (in Russian).
Barer GM, Denisov AB. Kristallograficheskii metod izucheniia sliuny [Crystallographic method of studying saliva]. Moscow: FGOU VUNMTs Roszdrava; 2008. 240 p. (in Russian).
Davis KM, Nakamura S, Weiser JN. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. Pneumoniae colonization in mice. J Clin Invest. 2011 Sep;121(9):3666-76. doi: 10.1172/JCI57761.
Derbise A, Pierre F, Merchez M, et al. Inheritance of the lysozyme inhibitor Ivy was an important evolutionary step by Yersinia pestis to avoid the host innate immune response. J Infect Dis. 2013 May 15;207(10):1535-43. doi: 10.1093/infdis/jit057.
Dainin K, Ide R, Maeda A, Suyama K, Akagawa M. Pyridoxamine scavenges protein carbonyls and inhibits protein aggregation in oxidative stress-induced human HepG2 hepatocytes. Biochem Biophys Res Commun. 2017 May 6;486(3):845-851. doi: 10.1016/j.bbrc.2017.03.147.
Ibrahim HR, Hamasaki K, Miyata T. Novel peptide motifs from lysozyme suppress pro-inflammatory cytokines in macrophages by antagonizing toll-like receptor and LPS-scavenging action. Eur J Pharm Sci. 2017 Sep 30;107:240-248. doi: 10.1016/j.ejps.2017.07.005.
Abaturov AE, Volosovets AP, Yulish EI. Induktsiia molekuliarnykh mekhanizmov nespetsificheskoi zashchity respiratornogo trakta [Induction of molecular mechanisms of non-specific protection of the respiratory tract]. Kyiv: Pryvatna drukarnja FO-II Storozhuk OV; 2012. 240 s. (in Russian).
Marushko YuV , Melnykov OF, Zelena NA, Movchan OS. Local therapy of acute pharyngitis. Sovremennaya pediatriya. 2011;(38):107. (in Russian).
Degtiarenko EV, Pershin SV, Iurina MS, Khoda S. Efficiency of Lizak in the treatment of catarrhal gingivitis in adolescents. Pytannja eksperymental'noi' ta klinichnoi' medycyny. 2012;16(2):267-270. (in Russian).
Suerkulov ES, Alymbaev ESh, Yuldashev IM, Jumaev AT, Mamyraliev AB, Bigishiev MP. Possibilities of using of preparation Lizak and other local immune suppression remedies on treatment of child with chronic recurrent aphtous stomatitis (literature review). Meditsina Kyrgyzstana. 2014;4(1):50-53. (in Russian).
Melnikov OF, Krivokhatskaya LD, Pysanko VN, et al. The research of antiseptic’s action, which contains lysozyme, on the mechanisms of antiviral immunity of tonsil’scells in vitro. Journal of ear, nose and throat diseases. 2015;(4):22-26. (in Russian).
Marushko YuV, Melnykov OF, Zelena NA, Movchan OS. Actual problems of chronic tonsillitis therapy of non-streptococcal etiology. Zdorov’ja Ukrai'ny. Pul'monologija, Alergologija, Rynolaryngologija. 2013;(21):58-59. (in Ukrainian).
Copyright (c) 1970 O.Ye. Abaturov, O.O. Ahafonova, N.M. Tokarieva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.